|
Clinical presentation |
Target BP |
Recommended drugs |
|
Accelerated (malignant) hypertension |
MAP reduced by 20%-25% |
– First choice: Labetalol or nicardipinea – Second choice: Nitroprusside or urapidila |
|
Hypertensive encephalopathy |
MAP reduced by 20%-25% |
– First choice: Labetalol or nicardipinea – Second choice: Nitroprusside |
|
Acute coronary event |
SBP <140 mm Hg
|
– First choice: Nitroglycerine or labetalol – Second choice: Urapidila |
|
Acute cardiogenic pulmonary edema |
SBP <140 mm Hg |
– First choice: Nitroglycerine or nitroprusside (with loop diuretic) – Second choice: Urapidila (with loop diuretic) |
|
Acute aortic dissection |
SBP <120, HR <60 beats/min |
– First choice: Beta-blocker (esmolol, propranolol); add nitroglycerine, nitroprusside, or nicardipinea if needed – Second choice: Labetalol or metoprolol |
|
Eclampsia and severe preeclampsia/HELLP |
SBP <160 mm Hg, DBP <105 mm Hg |
– Magnesium sulfate plus one or more of labetalol, nicardipine,a or oral nifedipine – Consider immediate delivery |
|
Notes: 1) Treatment in the ICU or an equivalent setting is mandatory. 2) Drugs are usually delivered IV. 3) BP reduction should occur immediately (or within several hours in case of accelerated/malignant hypertension). | ||
|
a Not available in Canada. | ||
|
Adapted from Eur Heart J. 2018;39(33):3021-3104. | ||
|
BP, blood pressure; DBP, diastolic blood pressure; HELLP, hemolysis, elevated liver enzymes, and low platelets; ICU, intensive care unit; IV, intravenous; MAP, mean arterial pressure; SBP, systolic blood pressure. | ||